Therapy Activation Specialist Tmtt-evoque (device Specialist; Germany - North/north-east)

Transcatheter Mitral & Tricuspid Therapies (TMTTs) are the future of Edwards - Estimated to be a more than $5 billion opportunity by 2028, Edwards will discuss its multiple transcatheter programs aimed at transforming care for the many patients suffering from mitral and tricuspid regurgitation. Since 2017 Edwards launched already multiple products - transformational therapies in Europe led . click apply for full job details